Ryan Brameier
Venture investor in Denver
Denver, Colorado
Ryan Brameier, Venture investor in Denver is an active investor based in Denver, Colorado. This profile covers what Ryan Brameier backs, at which stage, and how founders can reach out in 2026.
Ryan Brameier is a Fund Manager at Platte River Equity.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- SaaS & Enterprise
- Location
- Denver, Colorado
- Typical check
- $625K
How to reach Ryan Brameier
Angels and operators like Ryan Brameier reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Ryan Brameier
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Ryan Brameier invest in?
Ryan Brameier invests in SaaS & Enterprise, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Ryan Brameier invest at?
Ryan Brameier typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Ryan Brameier's typical check size?
Ryan Brameier typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Ryan Brameier?
Unlock Ryan Brameier's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.